For instance, combination of serum AFP expression with two potential biomarkers, Glypican-3 (GPC3) and miR-122, shows diagnostic potential for HCV-related early-stage HCC [109], while potent biomarker-based panels comprising serological AFP, miR-122, and circulating telomerase reverse-transcriptase (TERT) promoter mutations can be efficiently used for screening HBV-related HCC [109]. Here, GPC3 is linked to hepatocellular carcinoma.